Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark(Institute on Aging), Daniel Skovronsky(Eli Lilly (United States)), Michael J. Krautkramer, Eric M. Reiman(Alzheimer's Association), Matthew Flitter, Robert E. Coleman(University of Sheffield), Barry J. Bedell(McGill University), Adam Fleisher(Banner Alzheimer’s Institute), Michael J. Pontecorvo(Eli Lilly (United States)), Thomas G. Beach(Banner Sun Health Research Institute), Mark A. Mintun(Washington University in St. Louis), Ming‐Chi Lu(University of California, San Francisco), Anupa Arora, Marwan N. Sabbagh(Cleveland Clinic), Alan Carpenter, P. Murali Doraiswamy(Alzheimer’s Disease Neuroimaging Initiative), Carl Sadowsky(Nova Southeastern University), Abhinay D. Joshi, Julie A. Schneider(University of California San Diego)
Cited by 846
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
|Alzheimer s & Dementia|2012|3.2k
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
|Acta Neuropathologica|2011|2.9k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k